Zimmer Biomet stock maintains Market Outperform rating at JMP after Q2 beat

Investing.com - Zimmer Biomet (NYSE:ZBH), a medical device company with a market capitalization of $20.65 billion, maintained its Market Outperform rating and $125.00 price target at JMP Securities following strong second-quarter results. According to InvestingPro analysis, the stock appears slightly undervalued at current levels, with 16 analysts recently revising their earnings estimates upward.

The medical device company reported revenue growth of 3% year-over-year on an organic and currency neutral basis for Q2 2025, exceeding consensus estimates by approximately 1%.

Zimmer Biomet delivered adjusted earnings per share of $2.07, surpassing Street expectations of $1.98, representing a beat of about 5%.

The company raised its full-year sales and adjusted EPS guidance ranges by approximately 50 basis points and $0.20, respectively, at each midpoint.

Despite these upward revisions to reported figures, Zimmer Biomet maintained its organic constant currency revenue growth forecast at approximately 4% year-over-year.

In other recent news, Zimmer Biomet reported second-quarter earnings that surpassed analyst expectations. The company’s strong performance was driven by its U.S. hip and knee portfolios, as well as its global S.E.T. business. Following these results, Zimmer Biomet raised its full-year earnings guidance, indicating a positive outlook for the remainder of the year. In addition, Bernstein SocGen Group raised its price target for Zimmer Biomet to $105 from $100, reflecting a revised price-to-earnings multiple of 12.0x, up from the previous 11.5x. Despite maintaining a Market Perform rating, the upward revision suggests improved confidence in the company’s financial prospects. These developments highlight Zimmer Biomet’s ongoing momentum and the positive reception from analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.